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Lactic acidosis is a rare but potentially fatal com-
plication of highly active antiretroviral therapy
(HAART) in HIV-positive patients, with an estimated
incidence of 0.57—8.5 cases/1000 person years.1
Subclinical hyperlactataemia is more frequent,
occurring in 8—18.3% of patients receiving nucleo-
side-analogue reverse transcriptase inhibitors
(NRTIs), but most episodes are transient.2 Though
yet to be fully elucidated, the proposed mechanism
involves mitochondrial DNA depletion and inhibition
of respiratory complexes.3
In several studies, stavudine and didanosine,
alone or in combination, have been associated with
a greater risk of developing lactic acidosis, whereas
zidovudine, lamivudine and abacavir seem less
likely to be involved in such complications.4—8 Only
one previous case report of lactic acidosis asso-
ciated with tenofovir was found.9
A 60-year-old Caucasian man presented on 27
March 2004 to the emergency department of the
authors’ hospital with coma (Glasgow coma
score = 6) and dyspnea. He was apyrexial, his blood
pressure was 100/65 mmHg, pulse frequency 52,
SaO2 93% with oxygen in mask. Chest X-ray was
negative. Blood cultures and ethanol in the blood
samples taken in the emergency department were
negative; pO2 at the same time was 130 mmHg (nor-
mal range > 80 mmHg). He had been HIV-1 positive
since December 2000 (risk factor: heterosexual con-
tacts) and was diagnosed with AIDS in February 2001
for meningeal cryptococcosis and pulmonary pneu-
mocystosis. He was treated with various antiretro-
viral regimens: stavudine 40 mg b.i.d. plus lami-
vudine 150 mg b.i.d. plus nevirapine 200 mg b.i.d.
from15April 2001 to 24 July 2001; zidovudine 300 mg
b.i.d. plus lamivudine 150 mg b.i.d. plus didanosine
250 mgo.d. from7August 2001 to 15December 2001;
tenofovir 300 mgo.d. plus stavudine30 mgb.i.d. plus
nevirapine 200 mg b.i.d. from 15 May 2003. Abacavir
was substituted for stavudine on 21 October 2003 for1201-9712/$30.00 # 2005 International Society for Infectious Diseas
doi:10.1016/j.ijid.2004.09.010mild signs and symptoms of peripheral neuropathy.
Immunovirologic response and tolerance to the last
therapy were satisfactory (the last outpatient eva-
luation, performed on 19 March showed HIV-RNA
<20 copies/mL, CD4 cell count 225  106/L, normal
hepatic and renal functions, amylase within normal
range, mild anemia with a haemoglobin concentra-
tion of 9.6 g/dL).
Abnormal laboratory values on admission were
serum aspartate aminotransferase 160 U/L (normal
range 10—35), serum alanine aminotransferase
70 U/L (9—43), amylase 1087 U/L (5—220), lactate
dehydrogenase 1000 U/L (150—450), international
normalised ratio for prothrombin time 1.74, blood
pH 7.006, pCO2 41.4 mmHg (35—45 mmHg), sodium
bicarbonate 9.9 mmol/L (22—26), lactic acid
9.7 mmol/L (0.6—1.7). Antiretrovirals were discon-
tinued and intravenous fluids with glucose and
sodium bicarbonate were given.
Unfortunately, lacticacidosisworsenedandsevere
signs ofmulti-organ failure developed: 12 hours after
admission, a re-evaluation of laboratory parameters
showed serumaspartate aminotransferase 4440 U/L,
serum alanine aminotransferase 1332 U/L, serum
creatinine 3.37 mg/dL (0.6—1.3), amylase 2594 U/
L, lactate dehydrogenase 9392 U/L, blood pH 6.961,
pCO2 52.5 mmHg, sodium bicarbonate 11.2 mmol/L,
lactic acid 10.1 mmol/L; one hour later he died.
Tenofovir, an NRTI, is being increasingly used
among HIV-positive patients because of its favorable
resistance profile, convenience and low toxicity. In
particular, its low affinity for mitochondrial DNA
polymerase gmay explain the absence of mitochon-
drial toxicity both in vitro and in vivo studies.10,11
Even in the single previous report of lactic acidosis
associated with tenofovir,9 the patient was in fact
treated with stavudine and didanosine before and
during tenofovir-based HAART, and the authors
underline the fact that a tenofovir-induced increase
in didanosine concentration might indeed have led
to hyperlactacidaemia. In the patient reported
here, by contrast, stavudine was substituted with
abacavir, because of peripheral neuropathy, fivees. Published by Elsevier Ltd. All rights reserved.
Letter to the Editor 229months before the acute onset of lactic acidosis. To
the best of our knowledge, ours is the first report of
fatal lactic acidosis with so-called mitochondrial-
sparing HAART. Further investigations are needed to
elucidate possible pharmacokinetic interactions,
which might have magnified the mitochondrial toxi-
city of tenofovir and/or abacavir.
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